These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 32402161

  • 1. Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis.
    Cohen CR, Wierzbicki MR, French AL, Morris S, Newmann S, Reno H, Green L, Miller S, Powell J, Parks T, Hemmerling A.
    N Engl J Med; 2020 May 14; 382(20):1906-1915. PubMed ID: 32402161
    [Abstract] [Full Text] [Related]

  • 2. Response to Antibiotic Treatment of Bacterial Vaginosis Predicts the Effectiveness of LACTIN-V (Lactobacillus crispatus CTV-05) in the Prevention of Recurrent Disease.
    Hemmerling A, Wierzbicki MR, Armstrong E, Cohen CR.
    Sex Transm Dis; 2024 Jun 01; 51(6):437-440. PubMed ID: 38733973
    [Abstract] [Full Text] [Related]

  • 3. Sustained effect of LACTIN-V (Lactobacillus crispatus CTV-05) on genital immunology following standard bacterial vaginosis treatment: results from a randomised, placebo-controlled trial.
    Armstrong E, Hemmerling A, Miller S, Burke KE, Newmann SJ, Morris SR, Reno H, Huibner S, Kulikova M, Nagelkerke N, Coburn B, Cohen CR, Kaul R.
    Lancet Microbe; 2022 Jun 01; 3(6):e435-e442. PubMed ID: 35659905
    [Abstract] [Full Text] [Related]

  • 4. Effects of bacterial vaginosis-associated bacteria and sexual intercourse on vaginal colonization with the probiotic Lactobacillus crispatus CTV-05.
    Ngugi BM, Hemmerling A, Bukusi EA, Kikuvi G, Gikunju J, Shiboski S, Fredricks DN, Cohen CR.
    Sex Transm Dis; 2011 Nov 01; 38(11):1020-7. PubMed ID: 21992977
    [Abstract] [Full Text] [Related]

  • 5. Vaginal Lactobacillus crispatus persistence following application of a live biotherapeutic product: colonization phenotypes and genital immune impact.
    Armstrong E, Hemmerling A, Miller S, Huibner S, Kulikova M, Crawford E, Castañeda GR, Coburn B, Cohen CR, Kaul R.
    Microbiome; 2024 Jun 21; 12(1):110. PubMed ID: 38907268
    [Abstract] [Full Text] [Related]

  • 6. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection.
    Stapleton AE, Au-Yeung M, Hooton TM, Fredricks DN, Roberts PL, Czaja CA, Yarova-Yarovaya Y, Fiedler T, Cox M, Stamm WE.
    Clin Infect Dis; 2011 May 21; 52(10):1212-7. PubMed ID: 21498386
    [Abstract] [Full Text] [Related]

  • 7. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis.
    Sobel JD, Ferris D, Schwebke J, Nyirjesy P, Wiesenfeld HC, Peipert J, Soper D, Ohmit SE, Hillier SL.
    Am J Obstet Gynecol; 2006 May 21; 194(5):1283-9. PubMed ID: 16647911
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of vaginally administered lyophilized Lactobacillus crispatus IP 174178 in the prevention of bacterial vaginosis recurrence.
    Bohbot JM, Daraï E, Bretelle F, Brami G, Daniel C, Cardot JM.
    J Gynecol Obstet Hum Reprod; 2018 Feb 21; 47(2):81-86. PubMed ID: 29196153
    [Abstract] [Full Text] [Related]

  • 9. Vaginal fungi are associated with treatment-induced shifts in the vaginal microbiota and with a distinct genital immune profile.
    Armstrong E, Hemmerling A, Miller S, Huibner S, Kulikova M, Liu R, Crawford E, Castañeda GR, Coburn B, Cohen CR, Kaul R.
    Microbiol Spectr; 2024 Aug 06; 12(8):e0350123. PubMed ID: 38912808
    [Abstract] [Full Text] [Related]

  • 10. Lactic acid gel versus metronidazole for recurrent bacterial vaginosis in women aged 16 years and over: the VITA RCT.
    Armstrong-Buisseret L, Brittain C, Kai J, David M, Anstey Watkins J, Ozolins M, Jackson L, Abdali Z, Hepburn T, Griffiths F, Montgomery A, Daniels J, Manley A, Dean G, Ross JD.
    Health Technol Assess; 2022 Jan 06; 26(2):1-170. PubMed ID: 35057905
    [Abstract] [Full Text] [Related]

  • 11. BASIC study: is intravaginal boric acid non-inferior to metronidazole in symptomatic bacterial vaginosis? Study protocol for a randomized controlled trial.
    Zeron Mullins M, Trouton KM.
    Trials; 2015 Jul 26; 16():315. PubMed ID: 26210791
    [Abstract] [Full Text] [Related]

  • 12. Phase 1 dose-ranging safety trial of Lactobacillus crispatus CTV-05 for the prevention of bacterial vaginosis.
    Hemmerling A, Harrison W, Schroeder A, Park J, Korn A, Shiboski S, Cohen CR.
    Sex Transm Dis; 2009 Sep 26; 36(9):564-9. PubMed ID: 19543144
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of oral metronidazole with vaginal clindamycin or vaginal probiotic for bacterial vaginosis: randomised placebo-controlled double-blind trial.
    Bradshaw CS, Pirotta M, De Guingand D, Hocking JS, Morton AN, Garland SM, Fehler G, Morrow A, Walker S, Vodstrcil LA, Fairley CK.
    PLoS One; 2012 Sep 26; 7(4):e34540. PubMed ID: 22509319
    [Abstract] [Full Text] [Related]

  • 14. Connecting the Dots: Translating the Vaginal Microbiome Into a Drug.
    Lagenaur LA, Hemmerling A, Chiu C, Miller S, Lee PP, Cohen CR, Parks TP.
    J Infect Dis; 2021 Jun 16; 223(12 Suppl 2):S296-S306. PubMed ID: 33330916
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Antibiotic treatment for the sexual partners of women with bacterial vaginosis.
    Amaya-Guio J, Viveros-Carreño DA, Sierra-Barrios EM, Martinez-Velasquez MY, Grillo-Ardila CF.
    Cochrane Database Syst Rev; 2016 Oct 01; 10(10):CD011701. PubMed ID: 27696372
    [Abstract] [Full Text] [Related]

  • 17. Supplementation of standard antibiotic therapy with oral probiotics for bacterial vaginosis and aerobic vaginitis: a randomised, double-blind, placebo-controlled trial.
    Heczko PB, Tomusiak A, Adamski P, Jakimiuk AJ, Stefański G, Mikołajczyk-Cichońska A, Suda-Szczurek M, Strus M.
    BMC Womens Health; 2015 Dec 03; 15():115. PubMed ID: 26635090
    [Abstract] [Full Text] [Related]

  • 18. Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study.
    Larsson PG, Stray-Pedersen B, Ryttig KR, Larsen S.
    BMC Womens Health; 2008 Jan 15; 8():3. PubMed ID: 18197974
    [Abstract] [Full Text] [Related]

  • 19. Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosis.
    Chavoustie SE, Carter BA, Waldbaum AS, Donders GGG, Peters KH, Schwebke JR, Paull JRA, Price CF, Castellarnau A, McCloud P, Kinghorn GR.
    Eur J Obstet Gynecol Reprod Biol; 2020 Feb 15; 245():13-18. PubMed ID: 31812702
    [Abstract] [Full Text] [Related]

  • 20. Safety, tolerability, and acceptability of Lactobacillus crispatus CTV-05 (LACTIN-V) in pregnant women at high-risk of preterm birth.
    Bayar E, MacIntyre DA, Sykes L, Mountain K, Parks TP, Lee PP, Bennett PR.
    Benef Microbes; 2023 Mar 14; 14(1):45-56. PubMed ID: 36815494
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.